ARCHIVES

FDA Approves Votrient For Renal Cell Carcinoma

This article is from The Cancer Letter archive.

Vol. 35 No. 39 | October 23, 2009

Download PDF Visit The Full Archive

Related Articles

ICF Clement Joins Dynalectron In FCRF

January 9, 1987

Efaproxyn Improved Survival Of Patients With Brain Mets

October 29, 2004

Retrospective Data Clean-Up Can’t Help C225 Phase II Trial; Protocol Far Too “Fuzzy”.

February 15, 2002

Statistical Models Determine Stem-Cell Transplant Effectiveness

July 26, 2013

PDQ Evaluation to Cost NCI More Than Reported

June 29, 1990

Children of Male Cancer Survivors Have Highrt Risk of Birth Defects

February 25, 2011